metformin has been researched along with Keratosis, Oral in 2 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, L | 1 |
| Deng, Y | 1 |
| Ji, T | 1 |
| Zhou, H | 1 |
| Liu, W | 1 |
| Gutkind, JS | 1 |
| Molinolo, AA | 1 |
| Wu, X | 1 |
| Wang, Z | 1 |
| Nachmanson, D | 1 |
| Harismendy, O | 1 |
| Alexandrov, LB | 1 |
| Wuertz, BR | 1 |
| Ondrey, FG | 1 |
| Laronde, D | 1 |
| Rock, LD | 1 |
| Rosin, M | 1 |
| Coffey, C | 1 |
| Butler, VD | 1 |
| Bengtson, L | 1 |
| Hsu, CH | 1 |
| Bauman, JE | 1 |
| Hewitt, SM | 1 |
| Cohen, EE | 1 |
| Chow, HS | 1 |
| Lippman, SM | 1 |
| Szabo, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| M4OC-Prevent: Metformin for Oral Cancer Prevention[NCT02581137] | Phase 2 | 26 participants (Actual) | Interventional | 2016-06-10 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Number of participants with complete and partial clinical response to metformin intervention.~Criteria for complete and partial clinical response are:~Complete Response (CR): Disappearance of all evidence of lesion(s). Partial Response (PR): Greater than or equal to 50% reduction in the sum of the products of diameters of lesion(s) measurable at baseline. Non-measurable lesion(s) may not increase greater than or equal to 25% in size and no new lesion may appear." (NCT02581137)
Timeframe: Baseline to up to 14 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prevention (Extended-release Metformin Hydrochloride) | 4 |
"Number of participants with complete and partial histologic response to metformin intervention.~Criteria for complete and partial histologic response are:~Complete Response (CR): Complete reversal of dysplasia or hyperplasia to normal epithelium in the target lesion.~Partial Response (PR): Improvement of the degree of dysplasia or hyperplasia in the target lesion." (NCT02581137)
Timeframe: Baseline to up to 14 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Prevention (Extended-release Metformin Hydrochloride) | 14 |
1 trial available for metformin and Keratosis, Oral
| Article | Year |
|---|---|
Inhibition of mTOR signaling and clinical activity of metformin in oral premalignant lesions.
Topics: Administration, Oral; Biopsy; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gene Expre | 2021 |
1 other study available for metformin and Keratosis, Oral
| Article | Year |
|---|---|
Metformin and oral cancer: In reply with emphasis on an emerging role of an old drug in oral cancer chemoprevention.
Topics: Cell Transformation, Neoplastic; Chemoprevention; Humans; Leukoplakia, Oral; Metformin; Mouth Neopla | 2022 |